Regeneron Pharmaceuticals (REGN) Cash from Investing Activities (2009 - 2026)

Regeneron Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$428.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 166.24% year-over-year to -$428.9 million; the TTM figure through Mar 2026 stood at -$1.7 billion (down 1177.53% YoY), while the FY2025 annual figure was -$629.1 million, up 74.51% from the prior year.
• Cash from Investing Activities was -$428.9 million for Q1 2026 at Regeneron Pharmaceuticals, down from $220.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $647.5 million in Q1 2025 to a low of -$2.4 billion in Q2 2023.
• Historically, Cash from Investing Activities has averaged -$617.4 million across 5 years, with a median of -$428.9 million in 2026.
• Biggest YoY gain for Cash from Investing Activities was 629.61% in 2024; the steepest drop was 615.78% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$1.9 billion in 2022, then surged by 96.44% to -$66.2 million in 2023, then jumped by 629.61% to $350.6 million in 2024, then plunged by 37.16% to $220.3 million in 2025, then tumbled by 294.69% to -$428.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$428.9 million (Q1 2026), $220.3 million (Q4 2025), and -$402.9 million (Q3 2025), per Business Quant data.